To specify the SAHA therapeutic effect and mechanisms in glaucoma treatment, Fujimoto et al. (2021) perfused enucleated porcine eyes with 10 ng/mL recombinant porcine TGF-β2 with or without 5 μM SAHA for 72 h, and the results showed that TGF-β2 and SAHA simultaneous perfusion can significantly suppress the TGF-β2-induced decrease in AH outflow facility. Here, TGFB2 is linked to glaucoma.